Publication

Article

Cardiology Review® Online

September 2007
Volume24
Issue 9

Beginning antithrombotic therapy in an 84-year-old woman

An 84-year-old woman was admitted to the hospital because of fever, wheezing, and shortness of breath.

An 84-year-old woman was admitted to the hospital because of fever, wheezing, and shortness of breath. She had a history of hypertension, chronic atrial fibrillation, chronic obstructive pulmonary disease, and hypothyroidism that was attributed to the use of amiodarone (Cordarone, Pacerone). Her medications on admission were levothyroxine (Synthroid), short-acting beta agonists, ipratropium (Atrovent), enalapril (Vasotec), and aspirin.

Haemophilus influenzae

An electrocardiogram showed atrial fibrillation, with a ventricular rate of 108 beats/minute, right bundle-branch block, and ectopic ventricular beats. A chest x-ray showed mild cardiomegaly and peripheral infiltrates in the upper lobe of the left lung and the lingula. Laboratory tests showed the following values: hematocrit, 38%; white blood cell count, 17,300/mm3; platelet count, 140,000/mm3; sodium, 134 mmol/L; potassium, 4.2 mmol/L; and glucose, 147 mg/dL. An acute exacerbation of her symptoms because of pneumonia due to was diagnosed, and the patient was treated with ceftriaxone (Rocephin) 1 g twice a day plus levofloxacin (Levaquin) 500 mg/day.

According to the

, this patient would benefit from treatment with antithrombotic agents. Given her age and comorbid conditions, the benefits of long-term antithrombotic treatment were determined to outweigh the risks for this patient.

results of our study

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.